Elevation Oncology Company Overview
About Elevation Oncology
Elevation Oncology (NASDAQ:ELEV) is a biotechnology firm dedicated to advancing the discovery, development, and delivery of innovative cancer therapies. With a laser focus on addressing the unmet medical needs of patients battling genetically defined cancers, Elevation Oncology embarks on a mission to transform the landscape of targeted therapeutics. The company's flagship projects involve the development of precision medicine treatments, aiming to match patients with therapies specifically designed to target the genetic abnormalities driving their cancer. Spearheaded by a team of passionate scientists and clinicians, Elevation Oncology's overarching objective is to pave the way for a new era in oncology, where every patient's treatment is personalized, improving outcomes and quality of life.
Snapshot
Operations
Products and/or services of Elevation Oncology
- Development of novel therapeutics targeting specific genomic alterations in solid tumors to improve treatment outcomes.
- Collaboration with biotech and pharmaceutical companies to advance precision medicine in oncology.
- Clinical trials focused on evaluating the efficacy and safety of targeted cancer therapies.
- Partnership with academic institutions for cancer research and development of innovative oncology solutions.
- Utilization of cutting-edge technology and genetic insight to identify actionable genomic drivers in cancer.
- Offering educational resources and support programs for healthcare professionals and patients on the use of targeted therapies in oncology.
Elevation Oncology executive team
- Ms. Tammy Furlong CPA, P.M.P.Interim CEO, CFO, Principal Financial and Accounting Officer & Secretary
- Mr. Robert C. YangSenior VP & General Counsel